Source 1primary paper2025MED
Toolkit/rM3Ds
rM3Ds
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
The Gs-coupled DREADD, rM3Ds, modulates excitability in neuron subsets that are sensitive to downstream effectors of Gs protein.
Usefulness & Problems
Why this is useful
rM3Ds is a Gs-coupled DREADD described as modulating excitability in neuron subsets sensitive to downstream Gs effectors. In this paper it serves as the baseline comparator for the humanized hM3Ds design.; Gs-coupled chemogenetic modulation of neuronal excitability
Source:
rM3Ds is a Gs-coupled DREADD described as modulating excitability in neuron subsets sensitive to downstream Gs effectors. In this paper it serves as the baseline comparator for the humanized hM3Ds design.
Source:
Gs-coupled chemogenetic modulation of neuronal excitability
Problem solved
It provides chemogenetic control over Gs-linked neuronal excitability. This makes it a functional predecessor for the humanized receptor described here.; enables modulation of excitability in neuron subsets sensitive to downstream Gs effectors
Source:
It provides chemogenetic control over Gs-linked neuronal excitability. This makes it a functional predecessor for the humanized receptor described here.
Source:
enables modulation of excitability in neuron subsets sensitive to downstream Gs effectors
Problem links
enables modulation of excitability in neuron subsets sensitive to downstream Gs effectors
LiteratureIt provides chemogenetic control over Gs-linked neuronal excitability. This makes it a functional predecessor for the humanized receptor described here.
Source:
It provides chemogenetic control over Gs-linked neuronal excitability. This makes it a functional predecessor for the humanized receptor described here.
Published Workflows
Objective: Develop and evaluate a humanized Gs-coupled DREADD that retains chemogenetic function while improving translational suitability relative to the non-human rM3Ds backbone.
Why it works: The abstract frames the workflow as replacing the non-human rM3Ds backbone with a whole-sequence humanized receptor, then checking that ligand response remains comparable before testing circuit and behavioral function in vivo.
Gs-coupled chemogenetic activationactivation of the D1-MSN-mediated basal ganglia direct pathwaysequence humanizationcomparative ligand response profilingselective neuronal expressionmouse disease-model validation
Stages
- 1.Humanized receptor development(library_design)
The abstract states that the non-human nature of rM3Ds raises potential immunogenicity and tolerability concerns for clinical translation, motivating development of hM3Ds.
Selection: Whole-sequence humanization of a Gs-coupled DREADD to address translational concerns associated with the non-human rM3Ds backbone.
- 2.Comparative ligand response profiling(functional_characterization)
This stage checks whether humanization preserved the core ligand response behavior of the Gs-coupled DREADD before in vivo testing.
Selection: Comparable DREADD ligand response profile relative to rM3Ds.
- 3.Selective neuronal expression and circuit testing(confirmatory_validation)
After establishing comparable ligand response, the authors test whether hM3Ds can drive the intended neural circuit effect in vivo.
Selection: Ability of hM3Ds expressed in D1-MSNs to activate the basal ganglia direct pathway.
- 4.Disease-model behavioral validation(in_vivo_validation)
This stage tests whether circuit modulation by hM3Ds translates into beneficial behavioral effects in a disease model.
Selection: Alleviation of Parkinsonian phenotypes in a Parkinson's disease mouse model.
Steps
- 1.Develop whole-sequence humanized Gs-coupled DREADD hM3Dsengineered receptor
Create a humanized successor to rM3Ds to address translational concerns associated with the non-human backbone.
Humanization is the enabling design step before any functional comparison or in vivo validation can occur.
- 2.Compare hM3Ds ligand response profile with rM3Dsengineered receptor and comparator receptor
Determine whether humanization preserved DREADD ligand responsiveness relative to the predecessor receptor.
The abstract indicates this comparison was performed before in vivo testing to establish functional comparability after humanization.
- 3.Selectively express hM3Ds in D1 medium spiny neuronsexpressed chemogenetic receptor
Place hM3Ds in the relevant neuronal population for circuit-level testing.
Cell-type-selective expression is required before testing whether hM3Ds can activate the D1-MSN-mediated basal ganglia direct pathway.
- 4.Assess activation of the D1-MSN-mediated basal ganglia direct pathwaytested chemogenetic receptor
Confirm that hM3Ds expression in D1-MSNs produces the intended circuit-level effect.
Circuit activation is tested after selective expression and before concluding disease-model efficacy.
- 5.Evaluate Parkinsonian phenotypes in a Parkinson's disease mouse modeltherapeutically evaluated chemogenetic receptor
Test whether hM3Ds-mediated circuit modulation yields beneficial behavioral effects in a disease model.
Behavioral disease-model validation follows demonstration of intended circuit activation.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
No target processes tagged yet.
Input: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuator
Use requires receptor expression and a DREADD ligand. The abstract does not provide construct or delivery details.; requires DREADD ligand activation
The abstract states that its non-human backbone creates translational concerns about immunogenicity and tolerability. It is therefore presented as less suitable for clinical translation than the humanized variant.; non-human backbone raises potential immunogenicity and tolerability concerns for clinical translation
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Selective expression of hM3Ds in D1 medium spiny neurons activated the D1-MSN-mediated basal ganglia direct pathway.
hM3Ds has a comparable DREADD ligand response profile to rM3Ds.
Selective expression of hM3Ds in D1 medium spiny neurons alleviated Parkinsonian phenotypes in a Parkinson's disease mouse model.
This paper reports development of hM3Ds, a whole-sequence humanized Gs-coupled DREADD.
hM3Ds is presented as an effective and likely safer DREADD tool for research and future clinical applications.
Approval Evidence
1 source1 linked approval claimfirst-pass slug rm3ds
The Gs-coupled DREADD, rM3Ds, modulates excitability in neuron subsets that are sensitive to downstream effectors of Gs protein.
Source:
comparative functionsupports
hM3Ds has a comparable DREADD ligand response profile to rM3Ds.
Source:
Comparisons
Source-stated alternatives
The abstract presents hM3Ds as a humanized alternative to rM3Ds. No other direct experimental alternatives are discussed in the abstract.
Source:
The abstract presents hM3Ds as a humanized alternative to rM3Ds. No other direct experimental alternatives are discussed in the abstract.
Source-backed strengths
established Gs-coupled DREADD comparator for ligand response profiling
Source:
established Gs-coupled DREADD comparator for ligand response profiling
Compared with hM3Ds
The abstract presents hM3Ds as a humanized alternative to rM3Ds. No other direct experimental alternatives are discussed in the abstract.
Shared frame: source-stated alternative in extracted literature
Strengths here: established Gs-coupled DREADD comparator for ligand response profiling.
Relative tradeoffs: non-human backbone raises potential immunogenicity and tolerability concerns for clinical translation.
Source:
The abstract presents hM3Ds as a humanized alternative to rM3Ds. No other direct experimental alternatives are discussed in the abstract.
Ranked Citations
- 1.